Immunoassay Interference Blocker Market Size

Immunoassay Interference Blocker Market Size

Immunoassay Interference Blocker Market size was valued at USD 289.2 million in 2023, growing at a CAGR of 6.3% between 2024 and 2032, driven by factors such as the growing prevalence of chronic diseases such as cancer, cardiovascular diseases, and autoimmune disorders that necessitates accurate and reliable diagnostic methods. Immunoassays are commonly used for biomarker detection in these conditions, making interference blockers essential for improving diagnostic accuracy.

Moreover, continuous advancements in immunoassay technologies and materials lead to the development of more effective interference blockers, thereby driving market growth. For instance, in July 2023, the life science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, launched two new immunoassay interference blockers, K-Block, and Mouse-Free IgG. These innovative blockers are 100% animal-free and have equivalent or superior performance compared to traditional animal-derived blockers. Thus, availability of such products in the market will spur the industry growth.

 

Immunoassay interference blockers are substances or reagents used to minimize or eliminate non-specific binding, cross-reactivity, and interference in immunoassay-based assays. Immunoassays rely on the specific interaction between an antibody and its target antigen to detect and quantify analytes of interest in biological samples. Also, immunoassay interference can cause false positive and false negative test results, leading to misinterpretation and improper patient diagnosis. The most common causes of interference are due to human anti-mouse antibodies (HAMA), rheumatoid factor (rf), and heterophilic antibodies (ha).